Last month, the news broke that the anti-psychotic Abilify, thanks in part to direct marketing to consumers for depression, has become the best-selling drug in the United States, raking in roughly $7 billion a year. Yet as Jay Michaelson in the The Daily Beast pointed out recently, no one's sure how it may achieve its purported effects as an "augmented" treatment for depression.

The alarms about the dangerous and sometimes deadly side-effects of antipsychotics affecting children and the elderly, among others, have been mounting for years. But only very recently have mainstream health officials in the United States and in Britain started to express concerns about these medic...